62921-76-0

Basic information

• Product Name: m-PEG5-Tos
• Synonyms: m-PEG5-Tos
• CAS NO: 62921-76-0
• Molecular Formula: C₁₆H₂₆O₇S
• Molecular Weight: 362.43844
• Mol File: 62921-76-0.mol

Chemical Properties

• Boiling Point: 468.3±40.0 °C(Predicted)
• Appearance: /
• Density: 1.164±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: m-PEG5-Tos(CAS DataBase Reference)
• NIST Chemistry Reference: m-PEG5-Tos(62921-76-0)
• EPA Substance Registry System: m-PEG5-Tos(62921-76-0)

Safety Data

• Hazardous Substances Data: 62921-76-0(Hazardous Substances Data)

Upstream product

• 23783-42-8 tetraethylene glycol monomethyl ether 
• 98-09-9 benzenesulfonyl chloride 
• 5650-20-4 3,6,9,12-tetraoxatetradecan-1-ol 
• 98-59-9 p-toluenesulfonyl chloride 
• 87117-61-1 1-phenyl-2,5,8,11,14-pentaoxapentadecane 
• 86259-87-2 1-phenyl-2,5,8,11-tetraoxatridecan-13-ol 
• 112-60-7 Tetraethylene glycol 

Downstream Products

• 135733-61-8 2-(1,4,7,10,13-Pentaoxatetradecyl)benzaldehyde 
• 80392-33-2 1-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)benzene 
• 287171-13-5 (2S)-1-benzyloxy-2-(2-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}ethoxy)propane 
• 85030-56-4 3,6,9,12-tetraoxa-tridecylamine 
• 134874-49-0 2,5,8,11-tetraoxatridecane-13-thiol 
• 935279-99-5 dimethyl 5-(2,5,8,11-tetraoxatridecan-13-yloxy)isophthalate 
• 875753-80-3 C₃₃H₅₉BrO₁₅ 
• 875753-81-4 C₃₈H₆₈O₁₅Si 
• 203451-18-7 1,4-bis(chloromethyl)-2-methoxy-5-(tetraethoxymethoxy)benzene 
• 775324-81-7 1,4-bis(chloromethyl)-2,5-bis-(2-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}ethoxy)benzene 
• 869081-36-7 bis[4-(2,5,8,11-tetraoxatridecan-13-yloxy)phenyl]ethane-1,2-dione 
• 1070335-32-8 C₄₆H₅₈O₁₂ 
• 484046-55-1 methyl 3,4,5-tris(2-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}ethoxy)benzoate 
• 1438687-44-5 C₁₅H₂₅NO₄ 

Relevant articles and documents

A Modular Synthetic Route Involving N-Aryl-2-nitrosoaniline Intermediates Leads to a New Series of 3-Substituted Halogenated Phenazine Antibacterial Agents

Pathogenic bacteria demonstrate incredible abilities to evade conventional antibiotics through the development of resistance and formation of dormant, surface-attached biofilms. Therefore, agents that target and eradicate planktonic and biofilm bacteria are of significant interest. We explored a new series of halogenated phenazines (HP) through the use of N-aryl-2-nitrosoaniline synthetic intermediates that enabled functionalization of the 3-position of this scaffold. Several HPs demonstrated potent antibacterial and biofilm-killing activities (e.g., HP 29, against methicillin-resistant Staphylococcus aureus: MIC = 0.075 μM; MBEC = 2.35 μM), and transcriptional analysis revealed that HPs 3, 28, and 29 induce rapid iron starvation in MRSA biofilms. Several HPs demonstrated excellent activities against Mycobacterium tuberculosis (HP 34, MIC = 0.80 μM against CDC1551). This work established new SAR insights, and HP 29 demonstrated efficacy in dorsal wound infection models in mice. Encouraged by these findings, we believe that HPs could lead to significant advances in the treatment of challenging infections.

Photo-responsive host-guest complexation directs dynamic covalent condensation of phenyl boronic acid andd-fructose

Inspired by the way templates have been used to drive dynamic combinatorial libraries by molecular recognition, we exploited the photo-responsive host-guest interaction of an azo-based photoswitch with permethylated cyclodextrin to reversibly manipulate t

Self-assembly of Amphiphilic Porphyrins To Construct Nanoparticles for Highly Efficient Photodynamic Therapy

Hydrophobic photosensitizers greatly affect cell permeability and enrichment in tumors, but they cannot be used directly for clinical applications because they always aggregate in water, preventing their circulation in the blood and accumulation in tumor

OXAZINE-BASED WATER-SOLUBLE FLUOROPHORE COMPOUNDS FOR IN VIVO NERVE IMAGING

This invention provides novel oxazine-based, water soluble fluorophore compounds useful in in vivo nerve imaging, as well as compositions comprising them and methods for their use.

The effect of the donor moiety of DPP based polymers on the performance of organic electrochemical transistors

Organic mixed (ionic and electronic) charge conductors are the building blocks of state-of-the-art bioelectronic devices, including the organic electrochemical transistors (OECTs). Despite the interest in OECTs, the library of polymers that show efficient

Nanostructured Micelle Nanotubes Self-Assembled from Dinucleobase Monomers in Water

Despite the central importance of aqueous amphiphile assemblies in science and industry, the size and shape of these nano-objects is often difficult to control with accuracy owing to the non-directional nature of the hydrophobic interactions that sustain them. Here, using a bioinspired strategy that consists of programming an amphiphile with shielded directional Watson–Crick hydrogen-bonding functions, its self-assembly in water was guided toward a novel family of chiral micelle nanotubes with partially filled lipophilic pores of about 2 nm in diameter. Moreover, these tailored nanotubes are successfully demonstrated to extract and host molecules that are complementary in size and chemical affinity.

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Synthesis of water soluble and multi-responsive selenopolypeptides via ring-opening polymerization of N-carboxyanhydrides

We report here the synthesis of water soluble selenopolypeptides via the ring-opening polymerization of N-carboxyanhydrides. The oligoethylene glycol-bearing selenopolypeptides are thermally responsive in aqueous solutions with tunable lower critical solution temperatures. The polymers can also undergo rapid and reversible helix-coil transitions upon responding to the added redox cycle.

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

PROTEIN AGGREGATION INHIBITOR AND PROTEIN AGGREGATION INHIBITING METHOD

PROBLEM TO BE SOLVED: To provide a protein aggregation inhibitor capable of inhibiting protein aggregation and preparing a protein solution with a low viscosity. SOLUTION: The protein aggregation inhibitor contains a compound represented by the general formula (1) in the figure. SELECTED DRAWING: None COPYRIGHT: (C)2018,JPOandINPIT